Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.39 |
| ▸ | NPY1R | P25929 | 9/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.39 |
| ▸ | NPY2R | P49146 | 5/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799746 | 1.00 | NPY4R (0.39) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL1799745 | 1.00 | NPY4R (0.39) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL16260521 | 0.89 | NPY4R (0.38) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL8164682 | 0.87 | C3AR1 (0.40) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL117141 | 0.87 | C3AR1 (0.40) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL466294 | 0.87 | C3AR1 (0.40) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL1388278 | 0.84 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL8120411 | 0.84 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL22279914 | 0.84 | ALOX15 (0.41) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL21008931 | 0.84 | NPY4R (0.38) | NPY4RNPY1RNPY5RNPY2RALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498358-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | EXELIXIS, INC. (US) | 2009-03-03 | — | — | US | claimed |
| EP-1984500-A2 | ADAM10 AND ITS USES RELATED TO INFECTION | VANDERBILT UNIVERSITY (US) | 2008-10-29 | — | — | EP | claimed |
| WO-2007084488-A2 | ADAM10 AND ITS USES RELATED TO INFECTION | VANDERBILT UNIVERSITY (US) | 2007-07-26 | — | — | WO | claimed |
| US-20050227973-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2005-10-13 | — | — | US | claimed |
| EP-1461313-A1 | HUMAN ADAM-10 INHIBITORS | Exelixis, Inc. (US) | 2004-09-29 | — | — | EP | claimed |
| WO-2003051825-A1 | HUMAN ADAM-10 INHIBITORS | EXELIXIS, INC. (US) | 2003-06-26 | — | — | WO | claimed |
| US-8247451-B2 | ADAM10 and its uses related to infection | VANDERBILT UNIVERSITY (US) | 2012-08-21 | — | — | US | disclosed |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | VANDERBILT UNIVERSITY | 2009-09-03 | — | — | US | disclosed |
| US-20090143386-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2009-06-04 | — | — | US | disclosed |
| US-7498358-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | EXELIXIS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20050227973-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2005-10-13 | — | — | US | disclosed |
| EP-1461313-A1 | HUMAN ADAM-10 INHIBITORS | Exelixis, Inc. (US) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003051825-A1 | HUMAN ADAM-10 INHIBITORS | EXELIXIS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227973-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, ADAM9 | NPY4R 4209/4885NPY1R 2930/4885NPY5R 3474/4885 |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | ADAM10, ADAM12, ADAM17 | NPY4R 4819/4885NPY1R 4547/4885NPY5R 4645/4885 |
| US-20090143386-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, CASP10 | NPY4R 3571/4885NPY1R 2535/4885NPY5R 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.